Once daily oral investigational medication and study-related medical care may be provided at no cost to eligible patients.
You are between the ages of 18 and 55 years who has a current diagnosis of relapsing multiple sclerosis (RMS).
You are between the ages of 18 and 60 years who has a current diagnosis of non-relapsing secondary progressive multiple sclerosis (nrSPMS).
You are between the ages of 18 and 55 years who has a current diagnosis of primary progressive multiple sclerosis (PPMS).
The investigational medication of these trials, tolebrutinib, is an investigational drug. Its safety and efficacy have not been established and are being investigated in these phase III trials. Tolebrutinib has not been approved for the treatment of MS by any regulatory authority.
RMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – usually persist for a short period of time (from a few days to a few months) and are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms disappear and there is no apparent progression of the disease during the periods of remission.
Approximately 85% of people with MS are initially diagnosed with RRMS.
RMS can further evolve to non relapsing-SPMS, when symptoms are steadily getting worse (confirmed increase in disability is observed) and the attacks of new or increasing neurologic symptoms (also called relapses or exacerbations) are either missing or very rare.
PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms and initial MS diagnostic, without early relapses or remissions. Occasional relapse may occur (exceptionally) with no remission and continuous increase in disability.
MyMStrials.com would like to stay in-touch.
No SPAM, we don’t sell or rent your information. Fully private.